A1RG34 logo

argenx BOVESPA:A1RG34 Stock Report

Last Price

R$154.35

Market Cap

R$231.7b

7D

-0.9%

1Y

112.8%

Updated

23 Dec, 2024

Data

Company Financials +

A1RG34 Stock Overview

A biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. More details

A1RG34 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth6/6
Past Performance0/6
Financial Health4/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

argenx SE Competitors

Price History & Performance

Summary of share price highs, lows and changes for argenx
Historical stock prices
Current Share Price€154.35
52 Week High€159.68
52 Week Low€69.16
Beta0.25
1 Month Change8.84%
3 Month Change35.12%
1 Year Change112.84%
3 Year Changen/a
5 Year Changen/a
Change since IPO96.88%

Recent News & Updates

Recent updates

Shareholder Returns

A1RG34BR BiotechsBR Market
7D-0.9%-3.2%-2.1%
1Y112.8%-1.9%-11.7%

Return vs Industry: A1RG34 exceeded the BR Biotechs industry which returned -1.9% over the past year.

Return vs Market: A1RG34 exceeded the BR Market which returned -11.7% over the past year.

Price Volatility

Is A1RG34's price volatile compared to industry and market?
A1RG34 volatility
A1RG34 Average Weekly Movement6.7%
Biotechs Industry Average Movement9.2%
Market Average Movement5.1%
10% most volatile stocks in BR Market9.5%
10% least volatile stocks in BR Market2.8%

Stable Share Price: A1RG34 has not had significant price volatility in the past 3 months compared to the BR market.

Volatility Over Time: Insufficient data to determine A1RG34's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
20081,148Tim Van Hauwermeirenwww.argenx.com

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115.

argenx SE Fundamentals Summary

How do argenx's earnings and revenue compare to its market cap?
A1RG34 fundamental statistics
Market capR$231.72b
Earnings (TTM)-R$245.17m
Revenue (TTM)R$11.61b

20.0x

P/S Ratio

-945.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A1RG34 income statement (TTM)
RevenueUS$1.91b
Cost of RevenueUS$1.19b
Gross ProfitUS$721.98m
Other ExpensesUS$762.27m
Earnings-US$40.29m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Feb 27, 2025

Earnings per share (EPS)-0.67
Gross Margin37.83%
Net Profit Margin-2.11%
Debt/Equity Ratio0.8%

How did A1RG34 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 04:53
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

argenx SE is covered by 49 analysts. 28 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joel BeattyBaird
Charles Pitman-KingBarclays
Richard ParkesBNP Paribas Exane